INMB INmune Bio Inc.
Financings ·
The offering priced at $1.50 a share, and the warrants carry a $1.65 exercise price. The auditor's report on the 2025 accounts includes a going-concern paragraph, and cash was $18.4 million at June 30, 2026.
The prospectus puts the immediate dilution to new buyers at $4.97 per share. Cash was $19,377 thousand at March 31, 2025, against an accumulated deficit of $172,843 thousand.
INmune Bio is a clinical-stage biotechnology company developing product candidates designed to reprogram the innate immune system. Its lead program, CORDStrom, is a pooled, human umbilical cord-derived mesenchymal stromal cell platform for recessive dystrophic epidermolysis bullosa (RDEB), a pediatric orphan disease with no approved systemic treatments. CORDStrom has recently completed a pivotal, blinded, randomized cross-over trial, and the company is transitioning toward regulatory submission, including a Marketing Authorization Application in the United Kingdom and the European Union and a Biologics License Application with the U.S. Food and Drug Administration. The company's other clinical-stage platforms are XPro1595, a protein therapeutic that neutralizes soluble TNF and has completed Phase I and Phase II trials in Alzheimer's Disease, and INKmune, a natural killer cell-priming platform in an open-label Phase II trial for metastatic castrate-resistant prostate cancer. The FDA granted CORDStrom Rare Pediatric Disease and Orphan Drug designations.
| Product or program | What it is | Stage |
|---|---|---|
| CORDStrom | Pooled, human umbilical cord-derived mesenchymal stromal cells for RDEB | pivotal trial completed; transitioning toward regulatory submission |
| XPro1595 | Protein therapeutic that neutralizes soluble TNF for Alzheimer's Disease | Phase I and Phase II trials completed |
| INKmune | Natural killer cell-priming platform for metastatic castrate-resistant prostate cancer | open-label Phase II trial, nearing completion |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $50,000 | $14,000 |
| Research and development | $20.7 million | $33.2 million |
| Net income (loss) | -$45.9 million | -$42.1 million |
| Cash from operations | -$22.6 million | -$33.4 million |
| Cash and equivalents | $24.8 million | $20.9 million |
Our latest story on this, dated Oct 29, 2026: "INmune Bio raises $4.50 million in registered direct offering with warrants". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 29, 2026: "INmune Bio raises $4.50 million in registered direct offering with warrants". The story links the filing or release it is based on. Read the story.
INmune Bio Inc. trades under the ticker INMB on NASDAQ.
INmune Bio Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for INmune Bio Inc. is 1711754. Its filings are on SEC EDGAR.
27,753,789 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-06.
Our directory records INmune Bio Inc. under United States.
Our directory classifies INmune Bio Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for INmune Bio Inc. is US45782T1051.
aibio.space lists INmune Bio Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as NV.
INmune Bio is a clinical-stage biotechnology company developing product candidates designed to reprogram the innate immune system. Its lead program, CORDStrom, is a pooled, human umbilical cord-derived mesenchymal stromal cell platform for recessive dystrophic epidermolysis bullosa (RDEB), a pediatric orphan disease with no approved systemic treatments.
CORDStrom: Pooled, human umbilical cord-derived mesenchymal stromal cells for RDEB Stage: pivotal trial completed; transitioning toward regulatory submission.
XPro1595: Protein therapeutic that neutralizes soluble TNF for Alzheimer's Disease Stage: Phase I and Phase II trials completed.
$50,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 7.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Reported a financing. SEC Form 424B5. Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02,8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio